1. Home
  2. NOAH vs ENGN Comparison

NOAH vs ENGN Comparison

Compare NOAH & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NOAH

Noah Holdings Limited

HOLD

Current Price

$10.02

Market Cap

653.4M

Sector

Finance

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$7.59

Market Cap

647.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOAH
ENGN
Founded
2005
1999
Country
China
Canada
Employees
N/A
82
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
653.4M
647.1M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
NOAH
ENGN
Price
$10.02
$7.59
Analyst Decision
Hold
Buy
Analyst Count
2
6
Target Price
$11.00
$21.08
AVG Volume (30 Days)
184.1K
239.1K
Earning Date
05-27-2026
03-09-2026
Dividend Yield
5.75%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.71
N/A
P/E Ratio
$13.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.27
$2.66
52 Week High
$12.84
$12.25

Technical Indicators

Market Signals
Indicator
NOAH
ENGN
Relative Strength Index (RSI) 35.65 53.53
Support Level $9.64 $6.04
Resistance Level $12.26 $8.14
Average True Range (ATR) 0.42 0.51
MACD 0.00 0.18
Stochastic Oscillator 15.03 98.21

Price Performance

Historical Comparison
NOAH
ENGN

About NOAH Noah Holdings Limited

Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.

About ENGN enGene Holdings Inc.

enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Share on Social Networks: